Inhibition of miR-33a/b in non-human primates raises plasma HDL and reduces VLDL triglycerides

Cardiovascular disease (CVD) remains the leading cause of mortality in westernized countries, despite optimum medical therapy to lower LDL cholesterol. The pursuit of novel therapies to target this residual risk has focused on raising levels of HDL cholesterol in order to exploit its atheroprotectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rayner, Katey J., Esau, Christine C., Hussain, Farah N., McDaniel, Allison L., Marshall, Stephanie M., van Gils, Janine M., Ray, Tathagat D., Sheedy, Frederick J., Goedeke, Leigh, Liu, Xueqing, Khatsenko, Oleg G., Kaimal, Vivek, Lees, Cynthia J., Fernandez-Hernando, Carlos, Fisher, Edward A., Temel, Ryan E., Moore, Kathryn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235584/
https://www.ncbi.nlm.nih.gov/pubmed/22012398
http://dx.doi.org/10.1038/nature10486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235584/
https://www.ncbi.nlm.nih.gov/pubmed/22012398
http://dx.doi.org/10.1038/nature10486

Ejemplares similares